The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors
Authors: Jeong A. Kim, Youn Seon Choi, Dokyung Yoon, Kyung Hwan Cho
Journal: Annals of Internal Medicine (2005)

Letters18 October 2005The Risk for Myocardial Infarction with Cyclooxygenase-2 InhibitorsJeong A. Kim, MD, PhD, Youn Seon Choi, MD, PhD, Dokyung Yoon, MD, PhD, and Kyung Hwan Cho, MD, PhDJeong A. Kim, MD, PhDFrom Korea University, Seoul, Korea.Search for more papers by this author, Youn Seon Choi, MD, PhDFrom Korea University, Seoul, Korea.Search for more papers by this author, Dokyung Yoon, MD, PhDFrom Korea University, Seoul, Korea.Search for more papers by this author, and Kyung Hwan Cho, MD, PhDFrom Korea University, Seoul, Korea.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-8-200510180-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Lévesque and colleagues (1) reported that myocardial infarction risk was not increased with celecoxib. One recent study, Prevention of Spontaneous Adenomatous Polyps (PreSAP) (2), also showed that celecoxib does not increase the risk for cardiovascular events. However, we should consider the result of the Adenoma Prevention with Celebrex (APC) trial (3). In the APC trial, celecoxib use was associated with a dose-related increase in serious cardiovascular events; the authors concluded that this observation supported the hypothesis that sustained inhibition of prostacyclin with cyclooxygenase-2 (COX-2) inhibitors in twice-daily doses may increase cardiovascular risk compared with the once-daily doses ...References1. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142:481-9. [PMID: 15809459] LinkGoogle Scholar2. Pfizer Inc. Sporadic Adenomatous Polyposis Trial: PreSAP and APC. Celecoxib and Valdecoxib Cardiovascular Safety. New York: Pfizer Inc; 2005. Google Scholar3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-80. [PMID: 15713944] CrossrefMedlineGoogle Scholar4. Goldstein JL, Bello AE, Spalding W, Suh S, Fort JG. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. J Rheumatol. 2005;32:111-7. [PMID: 15630735] MedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Korea University, Seoul, Korea.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors: A Population Study of Elderly Adults Linda E. Lévesque , James M. Brophy , and Bin Zhang The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors Michal R. Pijak , Igor Huzicka , and Frantisek Gazdik The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors Ken Shinmura and Roberto Bolli The Risk for Myocardial Infarction with Cyclooxygenase-2 Inhibitors James M. Brophy , Linda E. Lévesque , and Bin Zhang Metrics 18 October 2005Volume 143, Issue 8Page: 615-616KeywordsAdenomasConflicts of interestDrug therapyMyocardial infarctionProstacyclinRisk management ePublished: 18 October 2005 Issue Published: 18 October 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...